Met in Biological Technology

SGX Presents Preclinical MET Data at AACR

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP ) presented abstract #4844 at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF...

Microbix Sales Grow 22% For Nine Months

...en in the news since the emergence of the H1N1 virus in April, a virus that met the WHO criteria of a pandemic strain," said Mr. Gastle. "There is a global... work with the technology over the next few months." The Company recently met with officials from Changsha National Biomedical Industrial Park in China t...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...reatment of ADHD in children and adolescents in the US. - On May 19, 2009 Shire announced that a randomized placebo controlled trial had met its primary objective, evaluating the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD ...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

...ients with Clostridium difficile infection at the European Congress of Clinical Microbiology and Infectious Diseases meeting, which showed the trial met its primary endpoint of achieving clinical cure compared to Vancocin(R). In addition, the top-line data showed that patients treated with fidaxomicin...

Cord Blood America Retires $2.53M Obligation

...t domestic stem cell storage companies. Our obligation was to pay the notes in full before the February 28, 2010 maturity date. We are happy to have met the obligation and have saved a significant amount of interest payments because of early payoff." "We have repeatedly said that decreasing debt...

Global Jatropha Hi-Tech Agricultural Training Programme (JWTP)

...Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met a lot of milestones since last year's event, and a number of alternative fe...Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met a lot of milestones since last year's event, and a number of alternative fe...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

...al Officer of Neurocrine Biosciences, "Most importantly, we find that the 250 mg once-daily dose, chosen to inform us about the upper limit of dosing, met the pre-defined threshold for bone impact." From an efficacy standpoint, the exploratory daily pain scales for Dysmenorrhea and Non-Menstrual ...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

...J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia. ...

Anesiva Receives NASDAQ Delisting Staff Determination Letter

...dpoint of reduced post-surgical pain versus placebo (p=0.03) following total knee arthroplasty (TKA) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005). ...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

...e its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo(TM) IR , successfully completed a Phase 3 study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurod...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...n has successfully completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. BENLYSTA has successfully met its primary endpoint in the first of two Phase 3 trials in systemic lupus erythematosus, and results of the second BENLYSTA Phase 3 trial are expected...

Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting

...saction remains subject to necessary global regulatory approvals and other customary closing conditions. On July 17, 2009, an important condition was met when European regulators announced that they had approved the merger. A closing date for the merger has not been announced, but the companies continu...

Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent

...esearch Group report and ARRIVE 1 and 2 registries. (2) In the TAXUS ALTAS Long Lesion Trial, the TAXUS Liberte Long (38mm) Stent met its primary endpoint of non-inferiority to the TAXUS Express control Stent in nine-month percent diameter stenosis (31.7% vs. 32.6%, p...

BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms

... bacteria like MRSA, VRE, ESBL, AmpC, KPC, etc in the hospital environment is again easily accomplished by Hospital Grade Ygiene(TM). In short, having met the EPA's AOAC Sporocidal Test standard in such a timely fashion is an impressive and significant accomplishment." "Killing these extremely ...

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

...healthcare facilities in South Asia. The study was directed by Prof. K. S. Vijayaragavan, Chief of Vascular Surgery at Sri Ramachandra University and met all regulatory approvals imposed by the Drug Controller of India and the Ethics Committee of Sri Ramachandra University, Chennai, India. Critical...

King and Pain Therapeutics Announce REMOXY(R) NDA Update

...wswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG ) and Pain Therapeutics, Inc. (Nasdaq: PTIE ) today announced that on July 2, 2009, King met with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). The ou...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

...le in the European Community and Australia, having met or exceeded each territory's requirements for safe...Medical Devices Directive 93/42/EEC, Filligent has met the stringent EU requirements for design, efficacy... The BioMask is also TGA-certified, meaning it has met or exceeded similar requirements in Australia. ...

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

...from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally. About Oncoscience AG ...

CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing

... of Lavasoft led a session on "Global Sales Strategy" to CSOFT's worldwide business development team. Will Knight of Microsoft (China) also met with the team to share marketing strategies and sales alignment to drive growth. "Information sharing is often confined within certain indust...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

...from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally. This press release may c...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... to Other Normal Organs - - All Patients in the First Two Cohorts Have met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients - ...r than in other normal organs. In addition, these patients have all either met or exceeded the expected median survival time of six months for recurrent G...

Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants

...the United States may be affected by at least moderate drought. In field trials conducted last year in the Western Great Plains, drought-tolerant corn met or exceeded the 6 percent to 10 percent target yield enhancement - about 7 to 10 bushels per acre in some of the key drought-prone areas in the United...

Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity

...a. The study supported the selectivity of rasagiline for inhibition of MAO-B at currently approved doses. "We are pleased with the results, which met our primary objectives," said Jon Congleton, general manager of Teva Neuroscience. "This study provides continuing evidence of the value of AZILECT. T...

BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products

.... All critical systems are supported by auto-switched generator power. Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to have met our cost, schedule, and quality goals for this construction project. We now have the capacity to produce up to 12,000 liters of HypoThermosol and Cry...

A billion-year ultra-dense memory chip

...nsmission electron microscope provided high-resolution imaging in real time while the memory device was in operation. In laboratory tests, this device met all the essential requirements for digital memory storage including the ability to overwrite old data. "We believe our nanoscale electromechanical ...

Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours

...4 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that it has met the goals of a $127,000 HTX/CIHR grant, reducing sample-preparation time from 2.5 days to less than eight hours. According to Xceed President and CEO,...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

...from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally. This press release may c...

Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform

...Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met a lot of milestones since last year's event, and a number of alternative fe...Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met a lot of milestones since last year's event, and a number of alternative fe...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... results presented and based on a median follow-up of 32 months, data were presented as summarized below. - The OGX-011 plus docetaxel arm met the primary endpoint of the trial given that 58% of patients treated with OGX-011 plus docetaxel achieved confirmed PSA declines of 50...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

...-8 cycles) was administered with the following safety results for OGX-427 as monotherapy: - Criteria for a maximum tolerated dose were not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of ad...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

...from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally. This press release may c...

Enerkem GreenField Alberta Biofuels Awarded Permit to Build World's First Commercial Municipal Waste-to-Biofuels Facility

...ovince of Alberta. The regulatory process entails a series of meetings and studies as well as a consultation with the public. The project successfully met all required regulatory environmental standards including air emissions and was awarded a permit allowing for construction and operation. In 2008, E...

goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites

...es as actively operating in India and maintains information on the company. "Screened by" indicates Maya Clinicals has visited the facility, met with senior management and reviewed the company's specific capabilities. Since launching in April, goBalto has acquired over 2,000 members who rep...

The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders

...s recently announced by Biovail) and provides shareholders with an opportunity to elect two highly qualified and independent directors (who have never met Mr. Melnyk). Mr. Haggis and Mr. Potter were selected as a result of the culmination of a professional search conducted entirely without Mr. Melnyk's i...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

...ent and Chief Executive Officer of PharmAthene, noted, "The first quarter of 2009 was a productive one for PharmAthene. In addition, we have recently met with senior officials at the Biomedical Advanced Research and Development Authority (BARDA) to discuss the pending FDA submission of our comprehensive...

Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09

...ology products." Influenza Vaccine Business The Hunan China manufacturing joint venture continues making progress as internal milestones are met by both partners. Microbix and Hunan are completing the pre-conditions that have been set for financing. Both levels of government in China are involv...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

...from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally. This press release may c...

Veteran-Owned Biotech Startup Company Charges Health Agency (NYSDOH) with Blackballing its Initiatives

...collaboration in the Middle East, which continues to have unfortunate repercussions. Additionally, research thrusts aimed at diabetic skin ulcers have met unusual resistance. And, recently, Ozonics experienced a setback in a U.S.- Australian endeavor using Ozonics' proprietary technology integrating micr...

Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study

...be updated and presented at ASCO this year, further studies are planned in patients with sarcoma." The primary statistical endpoint of the trial was met in late 2008. To meet the endpoint, at least three out of 52 patients had to experience stabilization of disease or better for more than six months. O...

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

...ts for both Alzheimer's and Parkinson's diseases are being conducted with key clinical centers. At the AAN meeting, Power3's Scientific Advisory Board met to plan the next phase of key validation trials. The Scientific Advisory Board currently includes Stanley H. Appel, M.D. Chair of Neurology at Methodi...